Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia [0.03%]
通过allostatic负荷估计慢性髓性白血病患者慢性压力的负担
Marisol Miranda-Galvis,Kellen C Tjioe,Muhannad Sharara et al.
Marisol Miranda-Galvis et al.
Despite advances in tyrosine kinase inhibitor (TKI) therapy, outcomes in chronic myeloid leukemia remain (CML) highly variable, underscoring the need to explore determinants beyond conventional clinical indicators. This study examined the r...
Robert Peter Gale,Andreas Hochhaus
Robert Peter Gale
Editorial
Leukemia. 2025 Sep 11. DOI:10.1038/s41375-025-02751-y 2025
Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML [0.03%]
纵向单细胞分析揭示了儿科急性髓系白血病的治疗抵抗性干细胞和肥大细胞及其潜在治疗方法
Denis Ohlstrom,Mojtaba Bakhtiari,Hope Mumme et al.
Denis Ohlstrom et al.
Pediatric acute myeloid leukemia (pAML) is a heterogeneous malignancy driven by diverse cytogenetic mutations. While identification of cytogenetic lesions improved risk stratification, prognostication remains inadequate with 30% of standard...
A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia [0.03%]
一种三维体外模型再现了儿童急性淋巴细胞白血病的体内特征和药物耐药表型
Magdalini Kanari,Iria Jimenez Garcia,Fabio D Steffen et al.
Magdalini Kanari et al.
Acute lymphoblastic leukemia (ALL) preferentially localizes in the bone marrow (BM) and displays recurrent patterns of medullary and extra-medullary involvement. Leukemic cells exploit their niche for propagation and survive selective press...
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias [0.03%]
携带PML-RARα的髓系细胞表现出代谢改变，可以针对难治性/复发性急性早幼粒细胞白血病进行治疗靶向
Alessandra Zaza,Giuseppe Zardo,Cristina Banella et al.
Alessandra Zaza et al.
At present there is no metabolic characterization of acute promyelocytic leukemia (APL). Pathognomonic of APL, PML::RARα fusion protein rewires metabolic pathways to feed anabolic tumor cell's growth. All-trans retinoic acid (ATRA) and ars...
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma [0.03%]
血浆置换可促进可溶性BCMA清除并有助于逆转多发性骨髓瘤抗BCMA免疫治疗原发耐药
Sven Neubert,Umair Munawar,Julia Mersi et al.
Sven Neubert et al.
Insights into germline predisposition to pediatric lymphoid malignancies [0.03%]
儿童淋巴样恶性肿瘤遗传易感性的研究进展
Roshina Thapa,Kim E Nichols,Richa Sharma
Roshina Thapa
Hematopoietic malignancies (HM) represent the most common form of pediatric cancer with lymphoid malignancies being the predominant subtype in kids. The majority of lymphoid malignancies are proposed to occur sporadically with environmental...
Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial [0.03%]
奥贝胆碱联合维奈克拉及低强度化疗治疗成人新诊断费城染色体阳性急性淋巴细胞白血病的单臂、单中心Ⅱ期临床试验校正说明文章
Xiaoyuan Gong,Wenbing Liu,Yuntao Liu et al.
Xiaoyuan Gong et al.
Published Erratum
Leukemia. 2025 Sep 5. DOI:10.1038/s41375-025-02696-2 2025
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome [0.03%]
修订后的国际预后评分系统与分子国际预后评分系统的不一致对骨髓增生异常综合征的影响
Alexandre Bazinet,Guillermo Montalban-Bravo,Alex Bataller et al.
Alexandre Bazinet et al.
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model [0.03%]
基于高龄和急性髓系白血病综合模型的患者特征分别接受维奈托克联合地西他滨与单纯使用地西他滨治疗的效果差异分析
Adriano Venditti,Jing-Zhou Hou,Pierre Fenaux et al.
Adriano Venditti et al.
Venetoclax plus azacitidine is recognized as standard of care for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC). However, some patients may still not be treated with venetoclax combinations due to fra...